<DOC>
	<DOCNO>NCT01628380</DOCNO>
	<brief_summary>Aim Study compare two-years disease-free survival Cytoreductive Surgery ( CRS ) Hyperthermic IntraPEritoneal Chemotherapy ( HIPEC , CDDP+Paclitaxel ) v CRS alone Stage IIIC unresectable epithelial tubal/ovarian cancer partial complete response 3 cycle 1st line chemotherapy ( CBDCA +Paclitaxel ) .</brief_summary>
	<brief_title>Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy Upfront Treatment Stage IIIC Epithelial Ovarian Cancer</brief_title>
	<detailed_description>Eligible : Female adult woman ( 18 70 year old ) patient , epithelial ovarian/tubal ( FIGO stage IIIC ) Fagotti modify Laparoscopic Scoring System ≥ 4 show complete partial clinical response ( RECIST 1.1 ) 3 cycle neoadjuvant chemotherapy ( Carboplatin+Paclitaxel ) . Duration recruitment : 2 year . Sample size calculate reach confidence level 95 % power 80 % , consider 45 % 75 % disease-free survival 2 year CRS CRS+HIPEC group respectively . Sample size 47 patient group . After CRS , patient adequate cytoreduction ( CC 0-1 , residual tumor ≤ 2.5mm ) randomize . Patients suboptimal cytoreduction ( CC 2-3 , residual tumor &gt; 2.5mm ) suitable randomization . The drug schedule elect current study Cisplatin ( CDDP ) ( 100 mg/m2 body surface area ) + Paclitaxel ( 175mg/m2 body surface area ) . Closed/open technique , preferred . Duration : 90 minute . Mean Intra-abdominal Temperature : 42°C . Primary Endpoint : 2-years disease-free survival . Secondary Endpoints : 1-year , 3- 5-years disease-free survival ; 1 month , 1-year , 3- 5-years overall survival ; toxicity induce HIPEC use NCI CTC criterion ; one month six month morbidity ; duration operation ; return bowel function ; length hospital stay ; return normal activity ; six month one year QOL , use SF-36 v1.0 ; percentage patient arm complete schedule postoperative chemotherapy ; Subgroup analysis : PCI ≤ 15 ; pt . ≤ 40yrs . Main topic Study : Focused upfront treatment primary disease . Select platinum-sensible patient ( responder platinum-based neoadjuvant chemotherapy ) . Take advantage NACT maximize chance cytoreduction . Standardized strategy CRS : radical surgery , associate surgical procedure need obtain zero ≤ 0.25cm residual tumor ( peritonectomy , bowel resection , diaphragmatic stripping , gastric resection , etc. ) . Pelvic peri-aortic lymphadenectomy choose standard procedure , warrant adequate staging . Compare effect HIPEC .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female adult woman ( 18 70 year old ) patient , EOC ( FIGO stage IIIc ) Fagotti modify Laparoscopic Scoring System ≥ 4 show complete clinical response ( cCR ) partial clinical response ( cPR ) 3 cycle ( Carboplatin+Paclitaxel ) neoadjuvant chemotherapy ; performance status ( ECOG ) 0 , 1 2 ; sign informed consent . refuse sign informed consent ; age &gt; 70 year age &lt; 18 year ; BMI &gt; 35 ; impossibility adequate followup ; presence active neoplasm ; active infection concurrent medical condition could interfere ability patient receive propose treatment accord protocol ; extraabdominal metastasis ( Stage IV ) ; performance status ( ECOG ) &gt; 2 ; complete bowel obstruction ; Abnormal bone marrow indices renal liver function ; ASA IV V .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>HIPEC</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Cytoreductive Surgery</keyword>
</DOC>